Andrew Skolarz, MD
Family Medicine · Chicago, ILNPI 1639582562
Payments from drug & device makers
Across 354 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$1K
- GSK$946
- Pfizer$912
- Amgen$821
- Boehringer Ingelheim$757
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,713100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 59 | $1,027 |
| Lilly USA, LLC | 46 | $1,025 |
| GSK | 47 | $946 |
| Pfizer | 34 | $912 |
| Amgen | 27 | $821 |
| Boehringer Ingelheim | 33 | $757 |
| Johnson & Johnson | 24 | $616 |
| Novo Nordisk | 11 | $255 |
| E.r. Squibb & Sons, L.L.C. | 9 | $223 |
| AbbVie(2 entities) | 10 | $182 |
| Novartis | 9 | $162 |
| Merck | 5 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Astellas Pharma US Inc | 3 | $68 |
| Sanofi Pasteur Inc. | 4 | $65 |
| Ardelyx, Inc. | 3 | $60 |
| Boston Scientific | 2 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,741 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $152,276 |
| JardianceEmpagliflozin | 52 | $69,936 |
| OzempicSemaglutide | 38 | $50,548 |
| XareltoRivaroxaban | 47 | $32,533 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $31,601 |
| EntrestoSacubitril/Valsartan | 16 | $25,959 |
| MyrbetriqMirabegron | 14 | $18,738 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 67 | $14,884 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,672 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $8,637 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 13 | $8,339 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $7,187 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $5,571 |
| Atorvastatin Calcium | 474 | $3,808 |
| Levothyroxine Sodium | 314 | $3,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $912 | $152,276178 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $757 | $77,12363 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $946 | $63,794119 claims |
| Novo NordiskOzempic | $255 | $50,54838 claims |
| Johnson & JohnsonXarelto | $616 | $32,53347 claims |
| NovartisEntresto | $162 | $25,95916 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $18,73814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chicago
- Bradley TorphyChicago$3M
- Frank PhillipsChicago$1.6M
- Ayoade AkereChicago$484K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
- Jacqueline OlivoChicago$165K
- Sameer PanjwaniChicago$136K
- Igor AltmanChicago$64K
- Juan RojasChicago$40K
- Mark SimonChicago$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.